CareLit · DOI-Nachweis · Zeitschrift für Gastroenterologie
Endoscopic outcome of medium term adalimumab therapy in patients with Crohn's disease. National data from Hungary
DOI 10.1055/s-0030-1254773
Bibliografische Angaben
Nachweis in CareLit
Autor:innenL Kiss, Z Czegledi, P Miheller, T Molnar, L Lakatos, K Palatka, K Farkas, T Szamosi, J Banai, Z Tulassay, M Papp, I Altojay, F Nagy, J Papp, P Lakatos
ZeitschriftZeitschrift für Gastroenterologie
Ausgabe05/2010
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Background/Aims: Adalimumab (ADA) is a fully human monoclonal antibody targeting tumor necrosis factor with proven efficacy in the treatment of Crohn's disease in clinical trials. In Hungary, regular long-term ADA therapy became available on an outpatient basis in December 2008 (since September 2008 as donation). In the present study our aim was to analyse the endoscopic outcome during 1-year ADA therapy in patients…
Zitieren
Zitierempfehlung
L Kiss, Z Czegledi, P Miheller, T Molnar, L Lakatos, K Palatka, K Farkas, T Szamosi, J Banai, Z Tulassay, M Papp, I Altojay, F Nagy, J Papp, P Lakatos (2010) Endoscopic outcome of medium term adalimumab therapy in patients with Crohn's disease. National data from Hungary. Zeitschrift für Gastroenterologie (05). https://doi.org/10.1055/s-0030-1254773
Mit CareLit weiterarbeiten